Healthcare Biz Cheat Sheet: FDA Approves Mylan’s New Allergy Drug, Spherix Shares Pop Over 100%
Myrexis (NASDAQ:MYRX) has announced plans to suspend any further development of its most advanced cancer drug candidate Azixa.
Spherix (NASDAQ:SPEX) has announced that its metabolic drug candidate SPX-106 achieved statistically significant reductions in VLDL and LDL cholesterol in genetically engineered mice prone to dyslipidemia. Shares in the microcap biopharmaceutical company have skyrocketed nearly 103%.
Sangamo Biosciences (NASDAQ:SGMO) shares are up after the company announced that results from its HIV/AIDS study will be presented at a conference in Chicago later this month.
A Mylan (NASDAQ:MYL) subsidiary has received FDA approval for its Promethazine Hydrochlorine tablets, which are used to treat perennial and seasonal allergies. The company plans to begin shipping the product immediately.